"Self-blocking" for PET imaging of cellular proliferation in the liver

Conclusions: Application of unlabeled FLT reduced the [18F]FLT uptake throughout the body. However, therapeutical dose of FLT has been applied to humans with a questionable safety profile. Titration and timing for the application of cold FLT needs to be investigated further for clinical application of "self-blocking" using large dose of cold FLT. Unlabeled CFA did reduce the liver background activity of [18F]-CFA as expected. CFA was conditionally approved to treat pediatric acute lymphoblastic leukemia, and can potentially be combined with [18F]CFA for clinical PET imaging of dCK-dependent proliferation in liver cancers. Based on the fact that about half of the TK2 actively exists in the cytosol, not inside the mitochondria, additional study is warranted to develop strategies for the reduction of liver background uptake of FMAU.
Source: Journal of Nuclear Medicine - Category: Nuclear Medicine Authors: Tags: Basic Oncology & amp; Translational (Poster Session) Source Type: research